1. Introduction {#sec1}
===============

Juvenile idiopathic arthritis (JIA), defined as unexplained joint swelling present in children under 16 years of age that persists for at least 6 weeks, is the most common rheumatic disease in children \[[@B1]\]. The worldwide prevalence of JIA is 7--400/100000 \[[@B2]\]. Immune dysfunction is considered to be the key pathogenesis of the condition, but the etiology remains unclear \[[@B3]\]. The goal of medical management in JIA includes maximizing the protection of children\'s daily functional activities, relief of pain, prevention or reduction of organ damage, and minimizing drug toxicity \[[@B4]\]. The treatment options for JIA include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, nonbiologic disease-modifying antirheumatic drugs (nonbiologic DMARDs), and biologic disease-modifying antirheumatic drugs (biologic DMARDs) (including TNF-*α* inhibitors, IL-1 inhibitors, IL-6 inhibitors, and other biologic compounds). The successful development of biologic DMARDs has provided a more efficient method for treating JIA \[[@B5]\].

*Paeonia lactiflora* Pallas, also named Chinese Peony, is a Chinese traditional medicine. In China, Korea, and Japan, the decoction of its dried root without the bark has been used in the treatment of rheumatoid arthritis (RA) for centuries and was approved to enter the market as a nonbiologic DMARD by the State Food and Drug Administration of China in 1998. A water or ethanol extract of the root, also known as total glucosides of peony (TGP), contains more than 15 components, of which paeoniflorin is the major active ingredient \[[@B6]\]. In recent years, some studies have demonstrated anti-inflammatory \[[@B7]--[@B9]\], immunomodulatory \[[@B10]--[@B12]\], hepatoprotective \[[@B13]--[@B18]\], and analgesic effects of TGP \[[@B19], [@B20]\] both in vitro and in vivo. The potential mechanisms of these effects include inhibition of the production of inflammatory mediators \[[@B13], [@B19], [@B21]\], suppression of overactivated immune-responses, balancing the function of helper T cells (Th) and suppressor T cells (Ts), and inhibition of oxidative stress and Ca^2+^ overload. Some clinical trials have shown that TGP can markedly improve the quality of patients\' lives and relieve the symptoms of JIA with lower incidences of side effects. However, no systematic review has yet been conducted.

The objective of this systematic review and meta-analysis is to pool the data from the included studies to examine the efficacy and safety of TGP compared with a control treatment or placebo in the treatment of JIA.

2. Materials and Methods {#sec2}
========================

To ensure the accuracy of our systemic review and meta-analysis, we conducted our review in compliance with the Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) statement \[[@B22]\] as much as possible.

2.1. Eligibility Criteria {#sec2.1}
-------------------------

Randomized controlled trials (RCTs) that compared the effects of TGP against a control treatment (placebo, NSAIDs, DMARDs, or glucocorticoids) in people with JIA were included in this review, regardless of dates, language, blinding, or publication status. Patients must have received TGP alone or with other active drugs for a minimum of 4 weeks. JIA was diagnosed according to the 2000 International League of Associations for Rheumatology (ILAR) classification criteria \[[@B23]\]. TGP was defined as a water or ethanol extract of Radix Paeoniae Alba, which in this review included TGP capsules and TGP tablets. We excluded trials that used other herbal extracts, and studies without outcomes data were also eliminated.

2.2. Information Sources and Search {#sec2.2}
-----------------------------------

We searched the following electronic databases from their inception to September 30th 2015: PubMed, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, ISI Web of knowledge, Chinese Biomedical Database (CBM), Chinese National Knowledge Infrastructure (CNKI), Wan Fang Database, and Chinese Science and Technique Journals Database (VIP). For the English databases, the search terms used were "Juvenile Idiopathic Arthritis" or "juvenile rheumatoid arthritis" or "JIA" or "JRA" or "Juvenile chronic arthritis" and "total glucosides of peony" or "total glucosides of Paeonia" or "TGP". For the Chinese databases, the key search terms were as follows: "you nian te fa xing guan jie yan" or "er tong te fa xing guan jie yan" (the Chinese name of JIA) and "bai shao zong gan" (which means total glucosides of peony) or "Pa fu lin" (a type of total glucosides of peony tablet). All search strategies were restricted to human clinical trials. To obtain any other additional articles, we manually searched all the references of the relevant studies identified. We also contacted the authors for the details of unpublished and ongoing studies.

2.3. Study Selection {#sec2.3}
--------------------

Two reviewers (Yongsong Cai and Qiling Yuan) first applied the eligibility criteria independently to screen the titles and abstracts of all the records and then sought the full text of studies meeting the inclusion criteria or that were ambiguous. The kappa value was used to measure the agreement between the two reviewers. Any inconsistencies were resolved by consensus or in consultation with a third reviewer (Peng Xu).

2.4. Data Collection Process {#sec2.4}
----------------------------

Two reviewers (Yongsong Cai and Qiling Yuan) independently extracted the data and entered it into a standard spreadsheet. The third reviewer (Jialin Zhu) verified the data accuracy. Any differences were resolved by consensus, and the authors were contacted to supplement any data lacking details.

2.5. Data Items {#sec2.5}
---------------

Information was extracted using structured data extraction tables including the following items: (1) study design; (2) patients\' general data (including age, sex, diagnostic methods, subtype, and severity of JIA); (3) inclusion and exclusion criteria; (4) intervention and comparator (including dose of TGP, duration of follow-up, and type of comparator (placebo or other medicine); the duration of follow-up was defined as one of three terms: short-term (4--8 weeks), intermediate term (9--26 weeks), or long-term (\>26 weeks), and the latest time point would be included if there were several time points in one term); (5) outcomes including changes of effectiveness (e.g., overall response rate, pain, tender joint count (TJC), swollen joint count (SJC), duration of morning stiffness (DMS), grip strength (GS), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and adverse effects (AEs)). Missing essential information was sought by contacting the authors.

2.6. Quality Assessment for Individual Studies {#sec2.6}
----------------------------------------------

Two authors (Yongsong Cai and Qiling Yuan) independently assessed the risk of bias in the individual studies with the Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 \[[@B24]\] according to the following aspects: random sequence generation, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. Each of the criteria was judged using three categories: low (low risk of bias), high (high risk of bias), and unclear (lack of information or uncertainty about the potential for bias). Studies with more categories judged as "low" were identified as superior. Agreement between the two authors was assessed using the kappa value. Any inconsistencies were resolved by consensus and discussion.

2.7. Data Synthesis and Analysis {#sec2.7}
--------------------------------

Data analyses were carried out with Stata/SE version 11 (STATA Corp., College Station, TX). We pooled the data with respect to the duration of follow-up (short term, intermediate term, and long term). For dichotomous outcomes, the odds ratios (ORs) and 95% confidence intervals (CIs) were used with the intention-to-treat (ITT) principles. For continuous data, the standard mean differences (SMDs) or the mean differences (MDs) and 95% CIs were calculated. SMDs were used when the same outcomes were assessed in a variety of ways, and if the outcomes were assessed on the same scale in all trials, the MDs were adopted. We used the *I* ^2^ statistic to quantify inconsistency across studies. A value of *I* ^2^ = 0% represents no observed heterogeneity, and larger values indicate increasing heterogeneity. When *I* ^2^ ≤ 25%, we reported the pooled results using a fixed-effect model; otherwise, a random-effects model was employed. If *I* ^2^ \> 50%, we further explored the possible factors of variation. Egger\'s test was used to assess potential publication bias. A value of *p* \< 0.05 signifies the existence of potential publication bias. A sensitivity analysis was performed to assess the robustness of the results for outcomes if applicable. A *p* value of less than 0.05 was considered significant for all analyses.

3. Result {#sec3}
=========

3.1. Study Selection {#sec3.1}
--------------------

Our initial search identified 158 studies, of which 48 duplicate studies were removed. After reading the titles and abstracts, 93 articles were excluded. Next, we read the full text of the remaining 17 articles, and 5 of them were excluded because they did not meet the inclusion criteria. One study had insufficient information (i.e., did not report any data about outcomes); the author was contacted for additional data but did not respond. Finally, 11 references \[[@B35]--[@B33]\] with a total of 590 participants were included (TGP: 308, control: 282) ([Figure 1](#fig1){ref-type="fig"}). Agreement on study selection between the 2 reviewers had a favorable consistency (kappa value = 0.90).

3.2. Study Characteristics {#sec3.2}
--------------------------

[Table 1](#tab1){ref-type="table"} listed the characteristics of the included studies that were published from 2004 to 2012. Eleven RCTs including 590 participants were conducted in China and published in Chinese. The majority of the studies were conducted as single-center trials, with only one study \[[@B25]\] conducted as a multicenter trial. Overall, the age of participants in the nine trials \[[@B34]--[@B28], [@B32]--[@B33]\] ranged from 1.5 to 14 years, and the average age was 8.8 years, although Shi and Ding \[[@B35]\] and Tong and Shui \[[@B27]\] did not report the average age. Males accounted for 55% of the participants in the nine \[[@B34]--[@B25], [@B28]--[@B33]\] studies, and two studies \[[@B35], [@B26]\] did not mention the gender distribution. The majority of trials showed the composition of each subtype of JIA, although five trials did not \[[@B35], [@B34], [@B26], [@B27], [@B32]\]. Two of the trials \[[@B35], [@B31]\] including 99 participants compared TGP alone with Methotrexate (MTX) alone. Nine studies had more than two types of treatment in the intervention or control groups as follows: TGP plus DMARDs versus DMARDs alone in 7 trials \[[@B25]--[@B28], [@B32]--[@B33]\]; TGP plus NSAIDs and glucocorticoids versus a control of NSAIDs and glucocorticoids in one trial \[[@B34]\]; TGP plus NSAIDs and DMARDs versus a control of NSAIDs and DMARDs in one trial \[[@B27]\]. Different doses of TGP, which ranged from 30 mg/kg/d to 60 mg/kg/d, were used in these studies. Moderate doses of TGP were used in most of the studies, but one study \[[@B28]\] did not mention the doses used. The total daily TGP intake was divided into two to three doses. Treatment duration ranged from four weeks to 12 months. Most studies used response rate, ESR, CRP, TJC, SJC, DMS, and AEs for measuring outcomes. The response rate was defined as the proportion of the number of participants who reached an efficacy average index 30 (EAI30) in all studies except Zang \[[@B31]\] (EAI50) and Shi and Ding \[[@B35]\] (EAI20). The EAI30 was defined as an average minimum of 30% improvement from baseline in all the included outcomes. Only one study \[[@B33]\] used the ACR70 to evaluate the effect of TGP.

3.3. Risk of Bias within Studies {#sec3.3}
--------------------------------

[Table 2](#tab2){ref-type="table"} shows the risk of bias across all studies. All the included clinical trials were associated with a high risk of bias. All the 11 included trials reported random sequence generation, but only one trial \[[@B29]\] provided the information regarding how randomization was performed. One trial \[[@B25]\] included the use of allocation concealment, and the processes used in the remaining studies were unclear. Blinding was unclear in all of the included studies. Agreement between the two authors for each aspect ranged from 72% to 100%, and the overall agreement was 90%.

3.4. Adverse Events {#sec3.4}
-------------------

Five trials \[[@B35], [@B31], [@B25], [@B32], [@B33]\] including 157 intervention patients and 134 controls reported adverse events. The pooled OR (95% CI) in the TGP plus MTX versus MTX alone subgroup, the TGP alone versus MTX alone subgroup, and the overall group was 0.63 (0.30 to 1.33), 0.14 (0.03 to 0.69), and 0.38 (0.17 to 0.82), respectively, which indicated that the intervention group had a lower incidence of AEs in the TGP alone versus the MTX alone subgroup and the overall group ([Figure 2](#fig2){ref-type="fig"} and [Table 3](#tab3){ref-type="table"}). The main AEs in intervention were gastrointestinal events which included nausea, abdominal distention, anorexia, and diarrhea. In the control group, the main AEs included liver function abnormalities, leucopenia, rash, stomatitis, and anorexia. The majority of these events were mild to moderate in intensity and did not require treatment.

4. Intervention Efficacy {#sec4}
========================

4.1. Cointervention versus Control {#sec4.1}
----------------------------------

Nine trials compared a cointervention of TGP and DMARDs or NSAIDs or glucocorticoids with a control as follows: TGP plus DMARDs versus DMARDs alone in 7 trials \[[@B25]--[@B28], [@B32]--[@B33]\]; TGP plus NSAIDs and glucocorticoids versus a control of NSAIDs and glucocorticoids in one trial \[[@B34]\]; TGP plus NSAIDs and DMARDs versus a control of NSAIDs and DMARDs in one trial \[[@B27]\].

### 4.1.1. The Overall Response Rate {#sec4.1.1}

Seven studies (*n* = 423) compared a cointervention and a control group \[[@B25], [@B28]--[@B33]\]. The overall response rates were assessed at each treatment term, which included short term (4--8 weeks), intermediate term (9--26 weeks), and long term (\>26 weeks), and the overall response rate at each term was as follows: OR = 1.55, 95% CI: 0.68 to 3.51; OR = 2.47, 95% CI: 1.22 to 5.0; and OR = 2.11, 95% CI: 0.56 to 7.93, respectively, with no significant heterogeneity (*I* ^2^ = 0%), which indicated that cointervention was favored in the overall response rate in the intermediate term ([Figure 3](#fig3){ref-type="fig"}). Sensitivity analysis was performed by using jackknife analysis in the intermediate term and, in most cases, removal of a study did not significantly change the result (OR ranged from 2.27 to 2.86, *p* \< 0.03), except in the study by Tong (OR = 2.04; 95% CI: 0.93 to 4.47; *p* = 0.074) ([Table 3](#tab3){ref-type="table"} and Supplementary Materials available online at <http://dx.doi.org/10.1155/2016/8292486>). Egger\'s test indicated no significant publication bias (coefficient = 0.59; SE = 0.90; *t* = 0.65; *p* = 0.545) in the intermediate term (Supplementary Materials).

### 4.1.2. ESR {#sec4.1.2}

Cointervention showed very large treatment effects for ESR compared to DMARDs alone \[[@B26], [@B28], [@B32]--[@B33]\] or DMARDs plus NSAIDs \[[@B27]\] (*n* = 379). The pooled MD for ESR was −4.21 mm/h (95% CI: −9.31 to 0.89 mm/h) in the short term, −3.36 mm/h (95% CI: −5.18 to −1.54 mm/h) in the intermediate term, and −3.72 mm/h (95% CI: −6.66 to −0.78 mm/h) in the long term. That is, the ESR in the cointervention groups was 3.36 mm/h lower than the ESR of the control groups in the intermediate term and 3.72 mm/h lower than the control groups at the long term, but heterogeneity existed in the intermediate term (*I* ^2^ = 58.1%, *p* = 0.026) and long term (*I* ^2^ = 91.7%, *p* = 0.001) ([Figure 4](#fig4){ref-type="fig"}). The source of the heterogeneity in the intermediate term was not apparent. A sensitivity analysis was performed by pooling the 6 studies \[[@B26]--[@B27], [@B30]--[@B33]\] with cointerventions versus DMARDs in the intermediate term, and the treatment effect was still significant, with an MD of −2.93 mm/h (95% CI: −4.92 to −1.44 mm/h) ([Table 3](#tab3){ref-type="table"} and Supplementary Materials). Egger\'s test indicated no significant publication bias (coefficient = −2.03; SE = 1.38; *t* = −1.47; *p* = 0.203) in the intermediate term (Supplementary Materials).

### 4.1.3. CRP {#sec4.1.3}

Seven studies \[[@B26]--[@B33]\] with a total of 379 participants compared the CRP between the cointervention groups and the groups using DMARDs alone \[[@B26], [@B28], [@B32]--[@B33]\] or DMARDs plus NSAIDs \[[@B27]\]. In the random-effects model, the SMDs in the short term, intermediate term, and long term were −0.53 (95% CI: −1.2 to 0.13), −1.02 (95% CI: −1.67 to −0.36), and −0.61 (95% CI: −1.19 to −0.03), respectively. That is, patients in the cointervention groups had a 1.02-unit significantly lower CRP in intermediate term and 0.61-unit lower CRP in long term than the patients in the control group ([Figure 5](#fig5){ref-type="fig"}). There was high heterogeneity in the intermediate term (*I* ^2^ = 88.4%). The source of this heterogeneity was unclear, but when two studies were removed \[[@B27], [@B29]\], the SMD was −0.49 (95% CI: −0.82 to −0.15, *I* ^2^ = 41.3%) ([Table 3](#tab3){ref-type="table"} and Supplementary Materials). In the sensitivity analysis limited to the 6 studies \[[@B26], [@B28], [@B32]--[@B33]\] with cointervention versus DMARDs in intermediate term, the SMD was −0.95 (95% CI: −1.7 to −0.2) ([Table 3](#tab3){ref-type="table"} and Supplementary Materials). No significant publication bias was found by Egger\'s test (coefficient = −7.5; SE = 4.66; *t* = −1.62; *p* = 0.166) in intermediate term (Supplementary Materials).

### 4.1.4. DMS {#sec4.1.4}

Four studies \[[@B26], [@B27], [@B32], [@B33]\] (*n* = 232) compared cointervention with DMARDs alone \[[@B26], [@B32], [@B33]\] or DMARDs plus NSAIDs \[[@B27]\] for the outcome of DMS and had a pooled MD of −6.28 min (95% CI, −16.77 to 4.21 min) in short term and −18.46 min (95% CI, −33.28 to −3.63 min) in intermediate term ([Figure 6](#fig6){ref-type="fig"}). The results indicated that cointervention had a shorter DMS than the control group in intermediate term. However, the results were heterogenous (*I* ^2^ = 82.7%). Sensitivity analysis was performed using the 3 studies \[[@B26], [@B32], [@B33]\] with cointervention versus DMARDs alone; the MD was −10.91 min (95% CI: −17.69 to −4.21) and *I* ^2^ = 0%, which indicated that Tong \[[@B27]\] was the main source of this heterogeneity ([Table 3](#tab3){ref-type="table"} and Supplementary Materials). There was no evidence of publication bias (coefficient = −0.07, SE = 4.7, *t* = −0.01, *p* = 0.99) (Supplementary Materials).

### 4.1.5. TJC {#sec4.1.5}

Two studies \[[@B26], [@B32]\] with a total of 87 patients compared TJC between the cointervention group and DMARDs alone. The MD was −2.19 (95% CI: −4.53 to 0.15) in short term and −2.99 (95% CI: −5.82 to −0.16) in intermediate term, meaning that the cointervention group had less TJC than the DMARD only group in intermediate term ([Table 3](#tab3){ref-type="table"} and Supplementary Materials).

### 4.1.6. SJC {#sec4.1.6}

Two studies \[[@B26], [@B32]\] compared SJC between the cointervention group and the group using DMARDs alone (*n* = 87). No effect was found in short term (MD = −2.41; 95% CI: −4.97 to 0.152) and intermediate term (MD = −3.05; 95% CI: −6.97 to 0.87) ([Table 3](#tab3){ref-type="table"} and Supplementary Materials).

### 4.1.7. Autoantibodies {#sec4.1.7}

Two studies (*n* = 93) \[[@B34], [@B33]\] compared IgG and IgA, and the pooled MDs were −0.90 (95% CI: −3.39 to 1.59) and −0.48 (95% CI: −1.05 to 0.10), respectively ([Table 3](#tab3){ref-type="table"} and Supplementary Materials).

### 4.1.8. Other {#sec4.1.8}

Tong and Shui \[[@B27]\] compared GS in intermediate term and the pooled MD was 1.83 kg (95% CI: 0.68 to 2.98; *p* = 0.002); Liu \[[@B28]\] compared the prednisone dosage and prednisone treatment duration and the pooled MD was −2.40 mg/d (95% CI: −3.75 to −1.05; *p* = 0.001) and −56 d (95% CI: −75.12 to −36.88; *p* \< 0.001), respectively. Only one study \[[@B33]\] described the response rate of ACR70 (OR = 3.61; 95% CI: 1.09 to 11.94; *p* = 0.04) and Juvenile Arthritis Disease Activity Score (JADAS) (MD = −1.75; 95% CI: −2.24 to −1.26; *p* \< 0.001) ([Table 3](#tab3){ref-type="table"} and Supplementary Materials).

4.2. TGP Compared with DMARDs Alone {#sec4.2}
-----------------------------------

### 4.2.1. The Overall Response Rate {#sec4.2.1}

Two studies \[[@B35], [@B31]\] with a total of 99 patients were pooled to compare TGP alone with MTX alone. The OR was 0.60 (95% CI: 0.12 to 3.03) in short term and 1.26 (95% CI: 0.29 to 5.47) in intermediate term with no significant heterogeneity (*I* ^2^ = 0%). That is, patients receiving TGP alone had a better response rate than patients who received MTX alone, but this finding did not reach statistical significance (*p* = 0.761 in intermediate term) ([Table 3](#tab3){ref-type="table"} and Supplementary Materials).

Only one study \[[@B31]\] described the result of continuous data in TGP versus MTX alone group, and the duration of treatment was 6 months. A significant difference was identified between TGP and the MTX alone group in terms of the pain score (*p* = 0.010; MD = −0.30; 95% CI: −0.53 to −0.07), dose of prednisone (*p* = 0.003; MD = −2.40 mg/d; 95% CI: −3.96 to −0.84), and course of prednisone (*p* \< 0.001; MD = −56 d; 95% CI: −77.71 to −34.29), signifying that the TGP group could shorten the course of prednisone, alleviate pain, and decrease the dose of prednisone. However, no effects were found in DMS (*p* = 0.316; MD = −3.36 min; 95% CI: −9.76 to 3.16), ESR (*p* = 0.169; MD = −4.40 mm/h; 95% CI: −10.67 to 1.87), or CRP (*p* = 0.651; MD = −1.6 mg/L; 95% CI: −8.53 to 5.34) ([Table 3](#tab3){ref-type="table"}).

5. Discussion {#sec5}
=============

To the best of our knowledge, this is the first systematic review and meta-analysis evaluating the efficacy and safety of TGP for the treatment of JIA. We pooled the results from 11 studies including 590 participants. To minimize the heterogeneity, three subgroups were set according to the treatment duration. The relevant clinical outcomes were studied, including ESR, CRP, DMS, SJC, TJC, autoantibodies, and treatment response rates, as well as other relevant clinical outcomes (i.e., GS, ACR70, pain score, and DAS). Overall, the results of this meta-analysis suggested favorable effects of TGP plus DMARDs or NSAIDs in patients with JIA in intermediate term (9--26 W), and the overall incidence of AEs was lower in intervention group. However, statistical significance was not attained in most of the results in short term and long term, especially in the TGP alone versus DMARD alone groups, which might be explained by the lack of sufficient studies included. In addition, the overall methodological quality was low. Therefore, caution should be exercised in interpreting these positive results.

In this meta-analysis, TGP combined with DMARDs or NSAIDs showed better effects on the ESR, CRP, DMS, and treatment response rates. Another highlight of our study was the finding that the intervention groups had a lower incidence of AEs (RR = 0.58, 95% CI: 0.38 to 0.91), particularly the incidence of hepatotoxicity (2/308 versus 6/282, RR = 0.31, 95% CI: 0.06 to 1.52). Some findings might explain the potential therapeutic effect of TGP in the treatment of JIA. Preclinical studies have shown that TGP displays immune-regulatory, anti-inflammatory, and hepatoprotective activities. In experimental arthritis rats, intragastric administration of TGP (25−100 mg/kg/d) for 7--14 days was demonstrated to notably diminish the severity of hind paw swelling and the scores of polyarthritis in a dose-dependent manner \[[@B7]--[@B10], [@B12], [@B36], [@B37]\]. The synovial infiltration of lymphocytes \[[@B8], [@B9], [@B12]\], hypertrophy of synovial membranes, and the formation of new blood vessels and pannus were also significantly inhibited by TGP \[[@B8], [@B9]\]. In vitro, paeoniflorin could induce apoptosis in murine T lymphocytes and Jurkat human T cell leukemia cells \[[@B11]\]. The most exciting effect of TGP was its hepatoprotective activity. Paeoniflorin has been shown to protect mice against*Schistosoma japonicum* egg-induced hepatic fibrosis by interfering with the IL-13 signaling molecule and decreasing the level of IL-13 \[[@B38], [@B39]\]. Other studies have also shown that paeoniflorin could protect mice against*Bacillus* Calmette-Guerin or lipopolysaccharide-induced liver injury \[[@B14], [@B40]\], which might be associated with the effects of inhibition of IL-1*β* and TNF-*α* release and the promotion of IL-10 production \[[@B21]\]. Recent research has also suggested that TGP could reduce the hepatotoxicity caused by combination treatment with Methotrexate and Leflunomide for active rheumatoid arthritis \[[@B18]\]. All the data supported the potential therapeutic effect of TGP in the treatment of JIA.

Three meta-analyses have been published on the efficacy and safety of TGP for the treatment of RA \[[@B41]--[@B43]\], but all of them have been published in Chinese. Among the three meta-analyses, two of them \[[@B41], [@B42]\] drew positive conclusions with the OR of TGP versus the control group for the overall response rates, which were 1.13 (95% CI: 1.04 to 1.24) and 2.65 (95% CI: 1.51 to 4.65), respectively. One trial \[[@B43]\] drew negative conclusions with the OR for the overall response rate (RR = 3.41, 95% CI: 0.77 to 15.10). The incidence of AEs in all the trials ranged from 0.41 to 0.66, and the incidence of hepatotoxicity ranged from 0.19 to 0.41. Most of the included studies indicated that TGP demonstrates beneficial effects on the symptoms of RA with a lower incidence of AEs, especially the incidence of hepatotoxicity. However, all of them also found that the incidence of diarrhea was higher in patients treated with TGP than in patients who were not treated with TGP. Our study resulted in similar conclusions. Considering that the treated subjects are children, the incidence of diarrhea should be noted when using TGP for the treatment of JIA.

The results of our meta-analysis should be treated with caution for several reasons. First, all the included trials were conducted in China, which was a potential selection bias, and might influence the application of TGP for patients in other countries. Second, the selected trials did not report ethical approval, which may weaken the validity of the results. Third, the methodological quality of the included studies was poor; while all of the selected studies were described as randomized controlled trials, only one trial \[[@B29]\] provided the information regarding how randomization was performed. Only one trial mentioned allocation concealment \[[@B25]\], and the blinding was unclear in all of the included studies. Fourth, in our study, we pooled the results without regard for the subtype of JIA, because treatment according to subtypes was not used in most of the included trials, which may affect the applicability for particular subtypes. Fifth, small sample sizes, insufficient numbers of included trials in each subgroup, and extensive heterogeneity in some results weaken the overall results of the review. Sixth, except for CRP, there was no other inflammatory factor, such as TNF-*α* or PGE2, which may weaken the persuasive. Lastly, the outcome measures used were inadequate, as only one trial used the American College of Rheumatology Pediatric (ACR Pedi) response criteria \[[@B33]\] and the Juvenile Arthritis Disease Activity Score (JADAS), and none of the included studies used tools for the assessment of quality of life, which is very important for evaluating the therapeutic effect, such as the Childhood Health Assessment Questionnaire (CHAQ), Child Health Questionnaire (CHQ), and Pediatric Quality of Life (PedsQL) \[[@B5]\]. All of these limitations may influence the application of TGP for treatment of JIA and weaken the validity of the results.

To effectively compare treatment options in different countries, future clinical RCTs should follow standardized and validated outcome measures and use accepted standards of trial design and reporting (CONSORT).

In conclusion, TGP is safe and efficacious for the treatment of JIA with few AEs. TGP, which has similar effects on nonbiologic DMARDs, is a special type of nonbiologic DMARD for the treatment of JIA.
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###### 

Characteristic of included studies.

  Study                             Case number (I/C)   Age (years)     Sex (male/female)   Subtype of JIA                       Intervention (I)                                                                                   Control (C)                                              Outcomes                                                                                                     Duration
  --------------------------------- ------------------- --------------- ------------------- ------------------------------------ -------------------------------------------------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ -----------
  Shi and Ding (2004) \[[@B35]\]    18/13               Unclear         Unclear             Unclear                              TGP 0.9 g/d, oral.                                                                                 MTX 10 mg/m^2^/w, oral                                   Overall response rate, AE                                                                                    6 W, 24 W
                                                                                                                                                                                                                                                                                                                                                                                                          
  Tang et al. (2004) \[[@B34]\]     16/16               9.5             17/15               Unclear                              TGP 30--60 mg/kg/d, oral. Naproxen 10--12 mg/kg/d, prednisone 1-2 mg/kg/d, oral.                   Naproxen 10--12 mg/kg/d, prednisone 1-2 mg/kg/d, oral    Overall response rate, autoantibody                                                                          2 M
                                                                                                                                                                                                                                                                                                                                                                                                          
  Zang (2004) \[[@B31]\]            42/26               8.6 (3--14)     32/36               Poly 34, Pauci 18, and systemic 16   TGP 0.03--0.06 g/kg/d, oral.                                                                       MTX 0.2--0.4 mg/kg/w, oral                               Overall response rate, ESR, CRP, DMS, prednisone dosage, prednisone treatment duration, pain score, and AE   6 M
                                                                                                                                                                                                                                                                                                                                                                                                          
  Cao et al. (2006) \[[@B25]\]      40/40               9.5 ± 3.0       52/28               Pauci 25, poly 11, and systemic 44   TGP 0.018 g/kg, twice a day orally; MTX 10 mg/m^2^ and folic acid 5 mg, once a week orally.        MTX 10 mg/m^2^ and folic acid 5 mg, once a week orally   Overall response rate, AE                                                                                    8 W, 24 W
                                                                                                                                                                                                                                                                                                                                                                                                          
  Li et al. (2008) \[[@B26]\]       18/18               7.1 ± 2.6       Unclear             Unclear                              TGP 0.015 g/kg, twice a day orally, MTX 10 mg/m^2^, and folic acid 5 mg, once a week orally.       MTX 10 mg/m^2^ and folic acid 5 mg, once a week orally   ESR, CRP, DMS, TJC, and SJC                                                                                  8 W, 12 W
                                                                                                                                                                                                                                                                                                                                                                                                          
  Liu (2008) \[[@B28]\]             35/35               8.6             41/29               Systemic 70                          TGP + MTX, oral dose (unclear).                                                                    MTX, oral dose (unclear)                                 Overall response rate, CRP, ESR, prednisone dosage, and prednisone treatment duration                        6 M
                                                                                                                                                                                                                                                                                                                                                                                                          
  Tong and Shui (2009) \[[@B27]\]   42/42               3--15           38/46               Unclear                              TGP 15--30 mg/kg, twice a day orally, Lef 0.2--0.4 mg/kg, and Mel 5--7.5 mg, once a week orally.   Lef 0.2--0.4 mg/kg, Mel 5--7.5 mg, once a week orally    Overall response rate, CRP, ESR, DMS, and GS                                                                 6 M
                                                                                                                                                                                                                                                                                                                                                                                                          
  Sun (2011) \[[@B32]\]             26/25               7.8 (1.5--14)   24/27               Unclear                              TGP 30--60 mg/kg/d, oral. MTX 10 mg/m^2^/w, oral.                                                  MTX 10 mg/m^2^/w, oral                                   Overall response rate, CRP, ESR, DMS, TJC, SJC, and AE                                                       26 W
                                                                                                                                                                                                                                                                                                                                                                                                          
  Zhao and Li (2011) \[[@B30]\]     17/15               8.1 ± 2.5       18/14               Poly 15, Pauci 10, and other 7       TGP 0.3 g, twice a day orally, MTX 10 mg/m^2^, once a week orally.                                 MTX 10 mg/m^2^ once a week orally                        Overall response rate, CRP, and ESR                                                                          6 M, 12 M
                                                                                                                                                                                                                                                                                                                                                                                                          
  Fang and Li (2012) \[[@B29]\]     23/22               8.1 ± 2.5       26/19               Systemic 45                          TGP 0.3 g, twice a day orally, MTX 10 mg/m^2^, once a week orally.                                 MTX 10 mg/m^2^ once a week orally                        Overall response rate, CRP, and ESR                                                                          6 M, 12 M
                                                                                                                                                                                                                                                                                                                                                                                                          
  Wang (2012) \[[@B33]\]            31/30               10.6 ± 2.9      38/23               Pauci 46, poly 13, and systemic 2    TGP 0.6 g, 3 times a day orally, MTX 0.25--0.8 mg/kg, once a week orally.                          MTX 0.25--0.8 mg/kg, once a week orally                  Overall response rate, CRP, ESR, DMS, autoantibody, ACR70, JADAS, and AE                                     8 W, 12 W

Pauci: pauciarticular; poly: polyarticular; Lef: Leflunomide; Mel: meloxicam; DMS: duration of morning stiffness; TGP: total glucosides of peony; MTX: Methotrexate; TJC: tender joint count; SJC: swollen joint count; GS: grip strength; AE: adverse effect; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; JADAS: Juvenile Arthritis Disease Activity Score.

###### 

Methodological quality of included trials.

  Author                            Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting   Other sources of bias
  --------------------------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- -----------------------
  Shi and Ding (2004) \[[@B35]\]    U                            U                        H                                        U                                H                         H                     H
  Tang et al. (2004) \[[@B34]\]     U                            U                        H                                        U                                U                         L                     U
  Zang (2004) \[[@B31]\]            U                            U                        U                                        U                                L                         L                     U
  Cao et al. (2006) \[[@B25]\]      U                            L                        U                                        U                                U                         L                     U
  Li et al. (2008) \[[@B26]\]       U                            U                        U                                        U                                H                         H                     U
  Liu (2008) \[[@B28]\]             U                            U                        H                                        U                                H                         U                     U
  Tong and Shui (2009) \[[@B27]\]   U                            U                        H                                        U                                H                         U                     U
  Sun (2011) \[[@B32]\]             U                            U                        U                                        U                                L                         L                     U
  Zhao and Li (2011) \[[@B30]\]     U                            U                        H                                        U                                U                         H                     U
  Fang and Li (2012) \[[@B29]\]     L                            U                        H                                        U                                U                         H                     U
  Wang (2012) \[[@B33]\]            U                            U                        H                                        U                                L                         L                     U

U: unclear; H: high risk; L: low risk.

###### 

Subgroup and sensitivity analysis.

  Treatment                       Outcomes                        Subgroup    Number of studies and participants             Effect size (SMD, MD, OR, or RR)   Effect size, *p* value   Heterogeneity, *I* ^2^ (%)   Heterogeneity, *p* value
  ------------------------------- ------------------------------- ----------- ---------------------------------------------- ---------------------------------- ------------------------ ---------------------------- --------------------------
  Cointervention versus control   Overall response rate                       7,423                                                                                                                                    
                                  Short term                      2,141       OR = 1.55, 95% CIs, 0.68 to 3.51               0.295                              0                        0.963                        
                                  Intermediate term               7,423       OR = 2.47, 95 CIs, 1.22 to 5.0                 0.012                              0                        0.862                        
                                  Long term                       2,77        OR = 2.11, 95% CIs, 0.56 to 7.93               0.27                               0                        0.872                        
                                  Intermediate term               6,339^\#^   OR = 2.04, 95% CI 0.93 to 4.47                 0.074                              0                        0.925                        
  ESR                                                             7,379                                                                                                                                               
                                  Short term                      1,36        MD = −4.21 mm/h, 95% CI, −9.31 to 0.89 mm/h    0.106                              ---                      ---                          
                                  Intermediate term               7,379       MD = −3.36 mm/h, 95% CI, −5.18 to −1.54 mm/h   \<0.001                            58.1                     0.026                        
                                  Long term                       2,77        MD = −3.72 mm/h, 95% CI, −6.66 to −0.78 mm/h   0.013                              91.7                     0.001                        
                                  Intermediate term               6,328^\#^   MD = −2.93 mm/h, 95% CI, −4.92 to −1.44 mm/h   \<0.001                            42.3                     0.123                        
  CRP                                                             7,379                                                                                                                                               
                                  Short term                      1,36        SMD = −0.53, 95% CI, −1.2 to 0.13              0.117                              ---                      ---                          
                                  Intermediate term               7,379       SMD = −1.02, 95% CI, −1.67 to −0.36            0.002                              88.4                     \<0.001                      
                                  Long term                       2,77        SMD = −0.61, 95% CI, −1.19 to −0.03            0.038                              35.9                     0.211                        
                                  Intermediate term               5,250^\#^   SMD = −0.49, 95% CI, −0.82 to −0.15            0.005                              41.3                     0.146                        
                                  Intermediate term               6,295^\#^   SMD = −0.95, 95% CI, −1.70 to −0.20            0.013                              88.7                     \<0.001                      
  DMS                                                             4,232                                                                                                                                               
                                  Short term                      1,36        MD = −6.28 min, 95% CI, −16.77 to 4.21 min     0.241                              ---                      ---                          
                                  Intermediate term               4,232       MD = −18.46 min, 95% CI, −33.28 to −3.63 min   0.015                              82.7                     0.001                        
                                  Intermediate term               3,148^\#^   MD = −10.91 min, 95% CI, −17.69 to −4.12 min   0.002                              0                        0.502                        
  TJC                                                             2,87                                                                                                                                                
                                  Short term                      1,36        MD = −2.19, 95% CI: −4.53 to 0.15              0.066                              ---                      ---                          
                                  Intermediate term               2,87        MD = −2.99, 95% CI: −5.82 to −0.16             0.038                              79.9                     0.026                        
  SJC                                                             2,87                                                                                                                                                
                                  Short term                      1,36        MD = −2.41, 95% CI: −4.97 to 0.152             0.065                              ---                      ---                          
                                  Intermediate term               2,87        MD = −3.05, 95% CI: −6.97 to 0.87              0.127                              92.8                     \<0.001                      
  IgG                             Intermediate term               2,87        MD = −0.90 g/L, 95% CI: −3.39 to 1.59 g/L      0.478                              80.7                     0.023                        
  IgA                             Intermediate term               2,87        MD = −0.48 g/L, 95% CI: −1.05 to 0.10 g/L      0.103                              85.2                     0.009                        
  GS                              Intermediate term               1,84        MD = 1.83 kg, 95% CI: 0.68 to 2.98 Kg          0.002                              ---                      ---                          
  Prednisone dosage               Intermediate term               1,70        MD = −2.40 mg/d, 95% CI: −3.75 to −1.05 mg/d   0.001                              ---                      ---                          
  Prednisone treatment duration   Intermediate term               1,70        MD = −56 d, 95% CI: −75.12 to −36.88 d           *p* \< 0.001                     ---                      ---                          
  ACR70                           Intermediate term               1,61        OR = 3.61; 95% CI: 1.09 to 11.94               0.035                              ---                      ---                          
  JADAS                           Intermediate term               1,61        MD = −1.75; 95% CI: −2.24 to −1.26               *p* \< 0.001                     ---                      ---                          
                                                                                                                                                                                                                      
  TGP alone versus MTX alone      Overall response rate                       2,99                                                                                                                                     
                                  Short term                      1,31        OR = 0.60, 95% CI: 0.12 to 3.03                0.537                              ---                      ---                          
                                  Intermediate term               2,99        OR = 1.26, 95% CI: 0.29 to 5.47                0.761                              0                        0.963                        
  DMS                             Intermediate term               1,68        MD = −3.36 min, 95% CI: −9.76 to 3.16 min      *p* = 0.316                        ---                      ---                          
  Pain score                      Intermediate term               1,68        MD = −0.30; 95% CI: −0.53 to −0.07             *p* = 0.010                        ---                      ---                          
  Doses of prednisone             Intermediate term               1,68        MD = −2.40 mg/d, 95% CI: −3.96 to −0.84 mg/d   *p* = 0.003                        ---                      ---                          
  Course of prednisone            Intermediate term               1,68        MD = −56 d, 95% CI: −77.71 to −34.29 d         *p* \< 0.001                       ---                      ---                          
  ESR                             Intermediate term               1,68        MD = −4.40 mm/h; 95% CI: −10.67 to 1.87 mm/h   *p* = 0.169                        ---                      ---                          
  CRP                             Intermediate term               1,68        MD = −1.6 mg/L; 95% CI: −8.53 to 5.34 mg/L     *p* = 0.651                        ---                      ---                          
  AEs                             Overall                         5,291       OR = 0.38, 95% CI: 0.17 to 0.82                0.014                              40.3                     0.153                        
                                  Cointervention versus control   3,192       OR = 0.63, 95% CI: 0.30, 1.33                  0.226                              0                        0.870                        
                                  TGP alone versus MTX alone      2,99        OR = 0.14, 95% CI: 0.03, 0.69                  0.016                              54.9                     0.137                        

^\#^Sensitivity analysis after some studies were dropped out. DMS, duration of morning stiffness; TGP, total glucosides of peony; MTX, Methotrexate; TJC, tender joint count; SJC, swollen joint count; GS, grip strength; AE, adverse effect; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; JADAS, Juvenile Arthritis Disease Activity Score.

[^1]: Academic Editor: Jae Youl Cho
